Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

50%

3 trials in Phase 3/4

Results Transparency

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3

3(50.0%)

Phase 1

2(33.3%)

Phase 2

1(16.7%)

6Total

Phase 3(3)

Phase 1(2)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT06956014Phase 3Not Yet Recruiting

Efficacy and Safety of VER-01 in the Treatment of Patients With Radicular Chronic Low Back Pain

Role: lead

NCT06475001Phase 2Completed

Dose-Response Characterization of VER-01 in the Treatment of Patients With Chronic Non-specific Low Back Pain

Role: lead

NCT05610813Phase 3Completed

Comparison of VER-01 to Opioids in Patients With Chronic Non-specific Low Back Pain

Role: lead

NCT04940741Phase 3Completed

Efficacy and Safety of VER-01 in the Treatment of Patients With Chronic Non-specific Low Back Pain

Role: lead

NCT04930796Phase 1Completed

Food Effect Study of VER-01 in Healthy Volunteers

Role: lead

NCT04930809Phase 1Completed

Single and Multiple Dose Study of VER-01 in Healthy Volunteers

Role: lead

All 6 trials loaded